Browse Articles

Redefining and advancing tree disease diagnosis through VOC emission measurements

Stoica et al. | Mar 27, 2025

Redefining and advancing tree disease diagnosis through VOC emission measurements

Here the authors investigated the use of an affordable gas sensor to detect volatile organic compound (VOC) emissions as an early indicator of tree disease, finding statistically significant differences in VOCs between diseased and non-diseased ash, beech, and maple trees. They suggest this sensor has potential for widespread early disease detection, but call for further research with larger sample sizes and diverse locations.

Read More...

Prediction of preclinical Aβ deposit in Alzheimer’s disease mice using EEG and machine learning

Igarashi et al. | Nov 29, 2022

Prediction of preclinical Aβ deposit in Alzheimer’s disease mice using EEG and machine learning

Alzheimer’s disease (AD) is a common disease affecting 6 million people in the U.S., but no cure exists. To create therapy for AD, it is critical to detect amyloid-β protein in the brain at the early stage of AD because the accumulation of amyloid-β over 20 years is believed to cause memory impairment. However, it is difficult to examine amyloid-β in patients’ brains. In this study, we hypothesized that we could accurately predict the presence of amyloid-β using EEG data and machine learning.

Read More...

Using the COmplex PAthway SImulator, Stage Analysis, and Chemical Kinetics to Develop a Novel Solution to Lower Tau Concentrations in Alzheimer’s Disease

Carroll et al. | Sep 28, 2020

Using the COmplex PAthway SImulator, Stage Analysis, and Chemical Kinetics to Develop a Novel Solution to Lower Tau Concentrations in Alzheimer’s Disease

In this study, the authors ask whether a Tau immunotherapy treatment, Hsp70 protein treatment, or dual treatment approach of both the Tau imunotherapy treatment and Hsp70 protein treatment leads to a greater reduction in Tau protein concentration in Alzheimer's disease. Overall, they conclude that the effectiveness of the treatment ultimately relies on the stage of Alzheimer’s.

Read More...

Potential Multifunctional Agents for Dual Therapy of Age-Related and Associated Diseases: Alzheimer’s Disease and Type 2 Diabetes Mellitus

Kumar et al. | Nov 13, 2019

Potential Multifunctional Agents for Dual Therapy of Age-Related and Associated Diseases: Alzheimer’s Disease and Type 2 Diabetes Mellitus

Studies show an age-related link between Alzheimer’s Disease and Type 2 Diabetes Mellitus with oxidative stress a characteristic of both. Here, methanolic fractionations and extracts of four Ayurvedic plants were assessed for their protective abilities using a number of in vitro assays. Extracts inhibited oxidative stress and reduced activity of key enzymes involved in the pathogenesis of both diseases in neuroblastoma cells.

Read More...

Mendelian randomization reveals shared genetic landscape in autism spectrum disorder and Alzheimer's disease

Lee et al. | Nov 04, 2024

Mendelian randomization reveals shared genetic landscape in autism spectrum disorder and Alzheimer's disease

Autism Spectrum Disorder (ASD) and Alzheimer's Disease (AD) are distinct conditions, but research suggests a link, as individuals with ASD are 2.5 times more likely to develop AD. A study employing genome-wide association studies and Mendelian randomization revealed shared genetic factors, particularly in synaptic regulation pathways, that may increase the risk of AD in those with ASD. These findings provide insights into the genetic underpinnings connecting the two disorders.

Read More...